Triple Negative Breast cancer (TNBC) Market Size, Epidemiology, Leading Companies, Drugs and Competi
- Ankit Nigam
- Jan 18, 2021
- 3 min read
(Albany, US) DelveInsight has launched a new report on “Triple Negative Breast Cancer (TNBC) Market Insights, Epidemiology, and Market Forecast-2030“
DelveInsight’s “Triple Negative Breast Cancer (TNBC) Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Triple Negative Breast Cancer (TNBC), historical and forecasted epidemiology as well as the Triple Negative Breast Cancer (TNBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Triple Negative Breast facts:
Market Size of TNBC in the 7MM was found to be 438 Million in 2017.
As per breastcancer.org, about 70% of breast cancers diagnosed in people with an inherited BRCA mutation, particularly BRCA1, are triple-negative.
As per several secondary sources, it can be concluded that TNBCs are significantly larger and of higher grade, but less likely to have lymph node metastases than non-TNBCs.
Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017.
DelveInsight has also estimated the Sub-type specific cases of TNBC, which are ER-, PR- and HER2- .
In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- sub-types.
Request for free Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
Scope of the Triple Negative Breast Report:
The report covers the descriptive overview of Triple Negative Breast Cancer (TNBC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Triple Negative Breast Cancer (TNBC) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Triple Negative Breast Cancer (TNBC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Triple Negative Breast Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Triple Negative Breast Cancer (TNBC) market
Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
Triple Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.
TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.
TNBC is characterized by various aggressive clinical pathologic features including onset at a younger age, higher mean tumor size, higher-grade tumors, and a higher rate of node positivity. Overall, TNBCs show an aggressive phenotype with a shorter time to relapse and metastatic disease than the more common hormone-receptorepositive invasive ductal carcinomas.
TNBC frequently metastasizes to the viscera, liver, lung or brain. However, this is not always the case as it may also have an oligometastatic phenotype closer to ER+ BC, with only lymph node and bone disease. TNBC is also heterogeneous in terms of time of recurrence. TNBC has a higher rate of recurrence in the first 5 years and a lower rate of recurrence afterwards. The pattern of late recurrence is generally associated with less aggressive disease, frequently with bone metastases.
Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
Some of the TNBC Companies:
Merck
Hoffmann-La Roche
Infinity Pharmaceuticals
CytoDyn
Treadwell Therapeutics
And Many Others
Triple Negative Breast Cancer Drugs Covered:
Pembrolizumab
Ipatasertib
IPI-549
Leronlimab (PRO 140)
CFI-400945
And Many Others
Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
Table of Contents:
Key Insights
Executive Summary of Triple Negative Breast Cancer (TNBC)
Competitive Intelligence Analysis for Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Cancer (TNBC): Market Overview at a Glance
Triple Negative Breast Cancer (TNBC): Disease Background and Overview
Patient Journey
Triple Negative Breast Cancer (TNBC) Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Triple Negative Breast Cancer (TNBC) Treatment
Marketed Products
Emerging Therapies
Triple Negative Breast Cancer (TNBC): Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Triple Negative Breast Cancer (TNBC)
KOL Views
Market Drivers
Market Barriers
Request for detailed TOC: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: info@delveinsight.com City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
Comments